RxDoctor Payments Data

Bayoan Ramos Parra, MD

Interventional Cardiology · Caguas, PRNPI 1831539469

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Stryker at 34.1% of the total. 2025 is the largest year on record at $13,908, 4.3 times the $3,229 reported in 2019.

$33,653in general payments, 2019–2025

Across 545 payments — averaging $61.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$11K
  • Abbott$8K
  • Medtronic$5K
  • Inari Medical, Inc.$3K
  • Boston Scientific$2K
  • Terumo Medical Corporation$1K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$8002%
  • Speaking & faculty fees$2,0006%
  • Travel & lodging$16,60949%
  • Food & beverage$13,80841%
  • Education$4351%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,653 in reported general payments places this provider in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$20,245
Medicare patients
69
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban168$122,031
EliquisApixaban104$71,987
EntrestoSacubitril/Valsartan79$67,117
JardianceEmpagliflozin54$53,359
FarxigaDapagliflozin Propanediol38$37,654
Repatha SureclickEvolocumab27$27,157
BrilintaTicagrelor28$23,164
Metoprolol Succinate258$4,813
Irbesartan109$3,442
Atorvastatin Calcium238$3,372
Rosuvastatin Calcium158$2,779
Candesartan Cilexetil17$2,628
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide63$2,619
Chlorthalidone96$2,447
ClopidogrelClopidogrel Bisulfate141$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$295$122,031168 claims
PfizerEliquis$8$71,987104 claims
AstraZenecaFarxiga, Brilinta$447$60,81966 claims
Boehringer IngelheimJardiance$278$53,35954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →